Close

Sign in
Sign up

Menu

Data Search
Content
Startup Concierge
Newsletters
Get intel

Home
News
Memo Therapeutics in a €26 million Series C led by Pureos Bioventures, with Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders

Memo Therapeutics in a €26 million Series C led by Pureos Bioventures, with Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders

Biotech Health services Manufacturing

Switzerland

Germany

United Kingdom

United States

Luxembourg

Investments

30 October 2023

Share:

Interested in more dealflow and deeper data sets from Europe? Please consider joining Nordic 9!

Memo Therapeutics (company)

Switzerland

Biotech Health services Manufacturing

Total investments received (USD): 112.24M

Round value (USD): 27.56M

Round investors: Verve Ventures Adjuvant Capital Redalpine Pureos Bioventures Swisscanto Invest Fresenius Medical Care Ventures GF Group Schroders Vesalius Biocapital Partners

Company: Memo Therapeutics

Industry: Biotech Health services Manufacturing

Related deals

Mabylon raised a total of €31.8 million in capital funding

Biotech Health services Pharma

Switzerland

Investments 13 July 2025

EvlaBio secures €21 million Seed Funding led by Kurma Partners as well as AdBio Partners, Boehringer Ingelheim, NRW.Venture (NRW.BANK) and HTGF .

Biotech Health services Manufacturing Pharma

Switzerland

Germany

France

Investments 02 July 2025

Sidebar

Verticals

Financial Services
Food Industry
Education
E-commerce
Health services
Marketplace

Benelux

Belgium
Netherlands

DACH

Austria
Germany
Switzerland

Nordics and Baltics

Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden

Western Europe

France
Ireland
Italy
Portugal
Spain
United Kingdom

About
Contact
Terms of service
Privacy policy

© All rights reserved Nordic 9 2016-2025. Made with in Stockholm

Top